SPOTLIGHT: Lyrica OK'd for epilepsy

Pfizer has received FDA approval to market Lyrica for adjunctive treatment of partial onset seizures in adults with epilepsy. The FDA approved Lyrica in December 2004 for the management of diabetic peripheral neuropathy and postherpetic neuralgia. Release

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.